
Natco net declines 43% on lower revenue
The Hindu
Natco Pharma reported a 43% decline in consolidated net profit for Q4 to ₹53 crore on the back of lower revenue in the base business. Total income dropped 25% to ₹359.7 crore. For FY21, the net profi
Natco Pharma reported a 43% decline in consolidated net profit for Q4 to ₹53 crore on the back of lower revenue in the base business. Total income dropped 25% to ₹359.7 crore. For FY21, the net profit slid 3.4% to ₹442.4 crore, while total revenue rose 6.6% to ₹2,155.7 crore (₹2,022.4 crore). Natco Pharma said it was able to sustain revenue during the year despite significant negative impact of the pandemic on the base business. The company said strong growth is expected in the current fiscal due to multiple high value product launches in the U.S, rebound in domestic India business with new products and contribution from Crop Health division.More Related News

‘Instead of accusing Gen-Z of lacking skills or discipline, we need to ask what drives them’ Premium
At a recent event held in the city, Cambridge University Press & Assessment launched an advisory panel comprising leaders from top global corporations, aiming to bridge the employability gap in India and better align academic output with industry needs. A whitepaper released at the event highlighted the growing importance of communication skills, the need for stronger collaboration between industry and universities, and strategies to bridge the persistent skill gap.